NIH Halts Large Cardiovascular Inflammation Reduction Trial (CIRT)
Futility or benefit? We may have to wait until November at American Heart Association. According to the article, the action was not based on any substantive safety concerns. This CIRT trial is assessing 3-point MACE in patients with a prior MI and either type 2 diabetes or metabolic syndrome treated with low dose methotrexate or placebo. Trial is run by Paul Ridker, who also headed the successful CANTOS trial testing the ability of anti-inflammatory canakinumab to reduce cardiovascular events.
BearDownAZÂ
